• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Alector Inc.

    4/28/26 4:06:02 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALEC alert in real time by email
    DEFA14A 1 alec-20260422.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

     

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

     

    ☐

    Definitive Proxy Statement

     

     

    ☒

    Definitive Additional Materials

     

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    ALECTOR, INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

     

    ☐

    Fee paid previously with preliminary materials

     

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     


    img214297469_0.jpg

     

    Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting of ALECTOR, INC.To Be Held On:June 12, 2024 at 8:00 a.m. Pacific Time Meeting live via the Internet - please visit https://web.lumiconnect.com/209804434 password: alector2024 (cap sensitive) COMPANY NUMBER ACCOUNT NUMBER CONTROL NUMBER This communication presents only an overview of the more complete proxy materials that are available to you on the Internet or by mail. We encourage you to access and review all of the important information contained in the proxy materials before voting. If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery please make the request as instructed below before May 26, 2024. Please visit http://www.astproxyportal.com/ast/22640, where the following materials are available for view: Notice of Annual Meeting of Stockholders Proxy Statement Proxy Card Annual Report on Form 10-K TELEPHONE: 888-Proxy-NA (888-776-9962) or 201-299-6210 (for international callers) TO OBTAIN PROXY MATERIALS: TO VOTE: TELEPHONE: 888-Proxy-NA (888-776-9962) or 201-299-6210 (for international callers) E-MAIL: help@equiniti.com WEBSITE: https://us.astfinancial.com/OnlineProxyVoting/ProxyVoting/RequestMaterialsONLINE: To access your online proxy card, please visit www.voteproxy.com and follow the on-screen instructions or scan the QR code with your smartphone. You may enter your voting instructions at www.voteproxy.com up until 11:59 PM Eastern Time the day before the meeting date. DURING THE MEETING: The company will be hosting the meeting live via the Internet this year. To attend the meeting via the Internet please visit https://web.lumiconnect.com/209804434 password: alector2024 (cap sensitive) and be sure to have available the control number. MAIL: You may request a proxy card by following the instructions above. 1. ELECTION OF DIRECTORS: NOMINEES: Louis J. Lavigne, Jr. Richard Scheller, Ph.D. Mark Altmeyer 2. Ratification of the appointment of Ernst & Young, LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024. 3. Advisory vote on executive compensation. THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE "FOR" ALL THE NOMINEES LISTED IN PROPOSAL 1 AND "FOR" PROPOSALS 2 AND 3.

     

     


    Get the next $ALEC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALEC

    DatePrice TargetRatingAnalyst
    4/15/2026Neutral → Overweight
    Cantor Fitzgerald
    3/10/2026$6.00Neutral → Buy
    BTIG Research
    10/22/2025$1.50Outperform → Neutral
    Mizuho
    10/22/2025Buy → Hold
    TD Cowen
    10/22/2025Overweight → Neutral
    Cantor Fitzgerald
    10/22/2025Outperform → Mkt Perform
    William Blair
    10/22/2025Buy → Neutral
    BTIG Research
    7/28/2025$3.50Neutral → Outperform
    Mizuho
    More analyst ratings

    $ALEC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Scheller Richard H was granted 10,833 shares, increasing direct ownership by 11% to 106,199 units (SEC Form 4)

    4 - Alector, Inc. (0001653087) (Issuer)

    6/3/26 7:08:32 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Rosenthal Arnon sold $172,191 worth of shares (87,216 units at $1.97), decreasing direct ownership by 4% to 2,367,206 units (SEC Form 4) to cover withholding tax

    4 - Alector, Inc. (0001653087) (Issuer)

    6/3/26 5:30:17 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Principal Accounting Officer Wong-Sarad Grace sold $17,813 worth of shares (9,184 units at $1.94) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,461 units (SEC Form 4) to satisfy tax liability

    4 - Alector, Inc. (0001653087) (Issuer)

    6/3/26 5:30:14 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alector Reports First Quarter 2026 Financial Results and Provides Business Update

    Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody for Alzheimer's disease (AD)), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's disease (PD)), and AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) $206.5 million in cash, cash equivalents and investments provide runway at least through 2027 SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a biotechnology company focused on developing therapies to counteract the devasting progression of neurodegeneration, today report

    5/7/26 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis

    --Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint –  --Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including an anti-Aβ antibody for Alzheimer's disease (AD), a GCase enzyme replacement therapy (ERT) for Parkinson's disease (PD), a tau siRNA for AD, an α-synuclein siRNA for PD, and an NLRP3 siRNA for multiple neurological and metabolic disorders, alongside several first-in-class discovery programs— SOUTH SAN FRANCISCO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodege

    4/29/26 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid antibody for Alzheimer's Disease), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's Disease) and AL064 (ABC-enabled Tau siRNA for Alzheimer's Disease) Independent interim futility analysis of the PROGRESS-AD Phase 2 trial of nivisnebart (AL101) in early Alzheimer's disease expected in the first half of 2026 $256.0 million in cash, cash equivalents and investments provide runway at least through 2027 SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Alector, Inc.

    2/25/26 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alector upgraded by Cantor Fitzgerald

    Cantor Fitzgerald upgraded Alector from Neutral to Overweight

    4/15/26 8:04:10 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector upgraded by BTIG Research with a new price target

    BTIG Research upgraded Alector from Neutral to Buy and set a new price target of $6.00

    3/10/26 8:36:07 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector downgraded by Mizuho with a new price target

    Mizuho downgraded Alector from Outperform to Neutral and set a new price target of $1.50

    10/22/25 7:10:52 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Alector Inc.

    SCHEDULE 13G/A - Alector, Inc. (0001653087) (Subject)

    5/14/26 4:57:27 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Alector Inc.

    8-K - Alector, Inc. (0001653087) (Filer)

    5/7/26 5:15:33 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by Alector Inc.

    424B5 - Alector, Inc. (0001653087) (Filer)

    5/7/26 5:13:54 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    Leadership Updates

    Live Leadership Updates

    View All

    Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer

    SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Neil Berkley, who has served as Alector's Chief Business Officer (CBO) since March 2024, and CBO and Interim Chief Financial Officer (CFO) since June 2025, has been appointed CFO, effective December 10, 2025. Mr. Berkley will continue to serve as CBO. "Neil has demonstrated exceptional leadership, judgment, strategic insight, and an unwavering commitment to Alector's mission," said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. "His

    12/12/25 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector Reports First Quarter 2024 Financial Results and Provides Business Update

    Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease, on track for Q4 2024 Strengthened leadership team with key appointments: Neil Berkley, M.S., M.B.A., named Chief Business Officer; Errol De Souza, Ph.D., and Mark Altmeyer, M.B.A., join Board of Directors $562.1 million in cash, cash equivalents and investments provide runway through 2026 SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported first quarter 2024 financial results and recent portfolio and business updates. As of March 31, 202

    5/8/24 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer

    SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Romano will lead the company's global clinical development strategy, including oversight of the clinical development, clinical operations, biometrics and digital science, and medical affairs functions. Dr. Romano will report to Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development of Alector. Dr. Romano's appointment is effective May 23, 2022. "We are delighted to welcome Gary to our executive leadership tea

    3/29/22 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    Financials

    Live finance-specific insights

    View All

    Alector Reports Second Quarter 2025 Financial Results and Provides Business Update

    On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no approved treatments Ongoing Phase 2 PROGRESS-AD trial of AL101 in early Alzheimer's disease expected to complete in 2026 Continuing to progress Alector Brain Carrier programs, including the company's anti-amyloid beta antibody, engineered GCase enzyme replacement therapy, and anti-tau siRNA $307.3 million in cash, cash equivalents, and investments provides runway into the second half of 2027 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NE

    8/7/25 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call

    SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2025, and provide a mid-year business update. The call will feature remarks from Ryan Darby, M.D., Associate Professor of Neurology and Director of the Frontotemporal Dementia Clinic at Vanderbilt University Medical Center, who will speak on the unmet need in frontotemporal dementia. A press release deta

    7/31/25 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226 in participants with early Alzheimer's disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates, including those targeting amyloid beta and replacing GCase $413.4 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company

    2/26/25 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alector Inc.

    SC 13G - Alector, Inc. (0001653087) (Subject)

    12/6/24 5:30:28 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alector Inc.

    SC 13G/A - Alector, Inc. (0001653087) (Subject)

    11/12/24 7:21:57 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alector Inc.

    SC 13G/A - Alector, Inc. (0001653087) (Subject)

    11/7/24 12:41:31 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care